Sign in
TerminatedPhase 2/3

Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

Key facts

Who runs it
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Where
Bangladesh, China, India, Indonesia, and Spain12 sites in 5 countriesChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 2/3
People taking part
369 people enrolled
Started
23 Jul 2020
Ended
26 Mar 2024
Type of study
Interventional, 2 groups
Treatments tested
  • BDB-001 Injection
  • Conventional treatment
Record updated
22 May 2024
Why it stopped
Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • 18 years old ≤ age ≤ 80 years old, both men or women
  • Confirmed SARS-CoV-2 infection, and meet at least one of the following criteria:; Confirmed severe COVID-19 in no more than 5 days who meets any of the following criteria:; Respiratory distress, RR ≥ 30 times/min; Finger oxygen saturation (SpO2) ≤93% in resting state(room air); Arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) ≤ 300 mmHg (1 mmHg = 0.133kpa) in supine position; Pulmonary imaging shows lesion progression > 50% within 24-48 hours; Symptoms,signs or chest imaging indicates ALI/ARDS
  • Requiring a mask oxygen therapy,high-flow nasal cannula oxygen therapy(HFNC)
  • The informed consent form signed

Who cannot take part

  • Subjects on current treatment with a complement inhibitor such as eculizumab within 1 month before randomization
  • A subject has used the following drugs within 2 weeks prior to screening procedures:; Calcineurin inhibitors (e.g., ciclosporin, tacrolimus, etc.); Proliferation inhibitors (e.g., everolimus, sirolimus, etc.); Anti-metabolic drugs (e.g., mycophenolate mofetil, mycophenolate, purine sulphate, etc.); Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF)/recombinant human granulocyte colony stimulating factor (rhG-CSF)
  • Subjects already progressed into critically severe COVID-19 Critical severe standards refer to FDA guidelines,as shown in Appendix 4 or sepsis and sepsis shock
  • Subjects with hypersensitivity history to any ingredient contained in the drug
  • Concomitant with the following situation:severe lung disease such as chronic obstructive pulmonary disease (moderate to severe type), lung cancers, active tuberculosis; severe cardiovascular and cerebrovascular disease: unstable angina pectoris, myocardial infarction, postcardiac surgery, cardiac function ≥ grade 3 (NYHA Classification), or had undergone heart surgery within 6 months before randomization; severe liver diseases (e.g. Child-Pugh score ≥ grade C); severe kidney diseases, such as renal insufficiency (GFR ≤ 15 mL/min/1.73m\^2); immune deficiencies or immune-related diseases : including organ or bone marrow transplantation, some autoimmune diseases, IgG4-related diseases, allergic alveolitis, vasculitis; malignancies
  • Subject who meets any of the following criteria will be excluded from the trial:
  • Pregnant or lactating woman
  • Subjects who have participated in other interventional clinical trials in the last 3 months or during this trial
  • Any other circumstances that the investigator considers inappropriate for the participation in this study

This trial has no sites in United States.

It has sites in 5 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This multi-center, open, randomized study will evaluate the efficacy and safety of BDB-001 injection in severe COVID-19 with severe pneumonia, or acute lung injury/acute respiratory distress syndrome. Patients will be randomized to two treatment arms (Arm A: Conventional treatment + BDB-001; Arm B: Conventional treatment alone).

The 2 groups in the trial

  • Treatment groupTreatment being tested

    Treatment: BDB-001 Injection

  • Control groupTreatment being tested

    Treatment: Conventional treatment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/III
Record updated
22 May 2024